Pouillon Lieven, Bossuyt Peter, Vanderstukken Joke, Moulin David, Netter Patrick, Danese Silvio, Jouzeau Jean-Yves, Loeuille Damien, Peyrin-Biroulet Laurent
a Department of Hepato-Gastroenterology , University Hospital Leuven , Leuven , Belgium.
b Imelda GI Clinical Research Centre , Imeldaziekenhuis Bonheiden , Bonheiden , Belgium.
Expert Rev Clin Pharmacol. 2017 Dec;10(12):1363-1374. doi: 10.1080/17512433.2017.1377609. Epub 2017 Sep 20.
More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We give an overview of the classification, the epidemiology and the diagnosis of IBD and SpA. The treatment goals, the pharmacologic management options and the available treatment guidelines in IBD patients with SpA are discussed. Expert commentary: The coexistence of IBD and SpA generates challenges and opportunities for both the gastroenterologist and the rheumatologist. The potential of drugs with a gut-specific mode of action in the treatment of IBD-related arthritis warrants further exploration.
超过半数的炎症性肠病（IBD）患者至少经历过一种肠外表现（EIM）。IBD患者中最常见的EIM是脊柱关节炎（SpA）。近50%的SpA患者存在微观肠道炎症。涵盖领域：我们概述了IBD和SpA的分类、流行病学及诊断。讨论了IBD合并SpA患者的治疗目标、药物管理选择及现有治疗指南。专家评论：IBD和SpA的共存给胃肠病学家和风湿病学家带来了挑战与机遇。具有肠道特异性作用模式的药物在治疗IBD相关关节炎方面的潜力值得进一步探索。
